Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration’s pre-license inspection of its San ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

H.C. Wainwright notes that Capricor Therapeutics (CAPR) announced that the FDA has completed its pre-license inspection of the company’s San Diego ...

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company announced the completion ...

Capricor Therapeutics shares dropped after the U.S. FDA inspected its San Diego manufacturing facility. Read more here.

Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 10.5% after the company announced that the FDA’s inspection of its San Diego manufacturing facility resulted in a Form 483 with ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

On May 5, 2025, Capricor issued a press release announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License ...

seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy”, the FDA had“confirmed its ...

This optimism is largely based on the potential of Capricor’s product, deramiocel™, which is expected to launch in the U.S. in late 2025. The company anticipates significant financial incentives upon ...